Compare Illumina, Inc. (ILMN) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vale SA — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Vale SA trades at $14.35 (market cap $62.26B). The key difference: Vale SA is far larger — about 2.1× Illumina, Inc.'s market cap, and Vale SA pays a 8.12% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | VALE | |
|---|---|---|
Market Cap | $28.96B | $62.26B |
Sector | Health | Basic Materials |
52-Week High | $205.10 | $17.82 |
52-Week Low | $91.00 | $9.71 |
Enterprise Value | $30.32B | $78.50B |
Dividend Yield | — | 8.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
VALE trades at $14.71, showing minimal daily movement with a slight decline of 0.07%. The stock faces technical bearish signals from moving averages while fundamentals reveal mixed performance with declining net income margins from 42.85% in 2022 to 5.11% in 2026, despite recent revenue stabilization. Recent earnings misses in Q4 2025 and Q1-Q2 2026 highlight operational challenges, though the company maintains strong cash flow generation of $8.8 billion from operations in 2025.
VALE presents a cautious investment case with analyst consensus leaning neutral (51.35% hold) despite a $16.79 price target suggesting 14% upside. Key opportunities include copper segment growth and disciplined capital returns, while risks involve rising operational costs, earnings volatility, and governance concerns highlighted by recent board disputes. The stock's valuation at 29.42 P/E appears stretched given profitability declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
